Researchers developed a new slow-release gel formulation of semaglutide that kept the medication active in obese rats’ bodies for 6 days instead of 1-2 days, allowing continuous weight loss over 20 days compared to a plateau with standard injections. According to Gram Research analysis, the sustained-release system also improved cholesterol and liver health markers, suggesting this approach could overcome weight loss plateaus and reduce injection frequency, though human testing is still needed.
Researchers developed a new way to deliver semaglutide, a popular weight-loss medication, using a special gel that releases the drug slowly over time. According to Gram Research analysis, this new delivery method kept the medication active in the body longer and helped lab animals continue losing weight even when they normally would have stopped. The gel also improved cholesterol and liver health markers. This breakthrough could mean fewer injections and better results for people struggling with weight loss plateaus, though human testing is still needed.
Key Statistics
A 2026 research study found that a sustained-release semaglutide gel extended the medication’s active time from 8 hours to 24 hours and maintained effective levels for 6 days in obese rats, compared to standard injections that peaked within 8 hours.
In diet-induced obese rats, the new sustained-release semaglutide formulation achieved continuous weight loss over 20 days, overcoming the weight loss plateau that occurred with non-sustained formulations around day 10-12.
The sustained-release semaglutide gel reduced total cholesterol (P < 0.01) and liver enzymes ALT and AST in obese rats, indicating improvements in dyslipidemia and fatty liver disease beyond weight loss alone.
A micro-needle jet injection device successfully delivered the sustained-release semaglutide gel with consistency and favorable safety in animal studies, showing no severe inflammation or tissue damage.
The Quick Take
- What they studied: A new way to deliver semaglutide using a special temperature-sensitive gel that slowly releases the medication into the body instead of all at once
- Who participated: Diet-induced obese rats were used to test the new delivery system and compare it to standard semaglutide injections
- Key finding: The new gel formulation kept semaglutide active in the body for 6 days instead of just 1-2 days, allowing animals to continue losing weight past the point where they normally would have stopped
- What it means for you: This research suggests a future treatment could require fewer injections while working better and longer, but this is early-stage research in animals—human studies are needed before this becomes available
The Research Details
Scientists created a special gel made from a material called P407 that changes from liquid to solid at body temperature. They mixed semaglutide into this gel and used a special injection device called a micro-needle jet injector to deliver it under the skin. The gel stays liquid at room temperature (easy to inject) but becomes solid at body temperature (slow release). They tested this in obese rats and compared results to rats that received regular semaglutide injections.
The researchers carefully measured how long the medication stayed in the animals’ bodies, how much was released each day, and whether the gel caused any harmful reactions. They also tested whether the medication still worked properly for weight loss and metabolic health when delivered this way.
This type of study is important because it tests a completely new delivery system before moving to human trials. It shows whether the engineering approach actually works in a living body and whether it’s safe enough to test in people.
Current semaglutide injections require frequent dosing and many people experience a weight loss plateau where their body adapts and stops losing weight. A longer-lasting delivery system could overcome this plateau by maintaining steady medication levels. This research approach is important because it combines pharmaceutical engineering with real-world testing to solve a practical problem patients face.
This is early-stage research conducted in laboratory animals, not humans. The study was published in a peer-reviewed pharmaceutical journal, which means other experts reviewed the methods. However, animal studies don’t always translate to human results. The researchers systematically tested multiple aspects (safety, drug release timing, effectiveness) which strengthens the findings. The lack of a specified sample size makes it harder to assess statistical power, but the consistent results across multiple measurements suggest reliable findings.
What the Results Show
The new gel formulation successfully extended how long semaglutide stayed active in the body. The medication’s half-life (time it takes for half the drug to leave your system) increased from about 8 hours to 15 hours. More importantly, the peak effectiveness time extended from 8 hours to 24 hours, meaning the medication worked at full strength for a full day instead of just a few hours.
Most significantly, obese rats receiving the new gel formulation continued losing weight for 20 days straight, while rats receiving regular semaglutide injections hit a weight loss plateau around day 10-12. This suggests the sustained-release system overcomes the adaptation problem that normally stops weight loss.
The injection device worked safely and consistently. The special micro-needle jet injector successfully delivered the thick gel without causing severe inflammation or tissue damage. The gel’s temperature-sensitive properties worked perfectly—staying liquid for easy injection but solidifying at body temperature to control release.
Beyond weight loss, the new formulation improved several health markers. Total cholesterol (TC) decreased significantly (P < 0.01, meaning very strong evidence). Liver enzymes ALT and AST both decreased, indicating the medication improved fatty liver disease. Glucose tolerance tests showed better blood sugar control without causing dangerously low blood sugar (hypoglycemia). These improvements suggest the sustained-release system may provide broader metabolic benefits beyond weight loss alone.
Previous semaglutide research shows the medication works well for weight loss but requires frequent injections and often causes plateaus. This study builds on that knowledge by solving two problems: extending the time between doses and preventing weight loss plateaus. The sustained-release approach is similar to other long-acting medications in different fields, but applying it to semaglutide is novel. The results align with the theory that steady medication levels work better than peaks and valleys.
This research was conducted only in rats, not humans, so results may not directly apply to people. The study didn’t specify exactly how many animals were tested, making it harder to assess statistical reliability. The research doesn’t address how the gel would work in real-world conditions like different body temperatures or individual variations. Long-term safety data beyond 20 days wasn’t reported. The study also didn’t compare this approach to other potential solutions for weight loss plateaus. Human clinical trials would be needed to confirm these promising early results.
The Bottom Line
This research is too early-stage to recommend for human use. It demonstrates proof-of-concept in animals that a sustained-release semaglutide gel could overcome weight loss plateaus. People currently taking semaglutide should continue their prescribed treatment as directed by their doctor. This research suggests future treatment options may become available, but realistic timelines for human trials and FDA approval are typically 3-5+ years from early-stage research.
This research is most relevant to people who experience weight loss plateaus with current semaglutide treatment, people who struggle with frequent injections, and those with metabolic complications like fatty liver disease. It’s also important for pharmaceutical companies developing obesity treatments and healthcare providers treating obesity. People without weight loss challenges or those not taking semaglutide don’t need to act on this information yet.
This is early-stage research. If development continues successfully, animal safety studies might take 1-2 years, followed by human clinical trials (3-5+ years), and then FDA review. Realistic timeline for potential human availability: 5-10+ years from publication. Don’t expect this treatment option soon, but it represents promising progress.
Frequently Asked Questions
How does the new semaglutide gel work differently from regular semaglutide injections?
The new gel uses a temperature-sensitive material that stays liquid at room temperature for easy injection but solidifies at body temperature to slowly release semaglutide over 6 days instead of 1-2 days. This extended release maintains steady medication levels, preventing the weight loss plateau that occurs with standard injections.
Will this new semaglutide delivery system be available soon?
This is early-stage research in animals. Realistic timeline for human availability is 5-10+ years, including animal safety studies (1-2 years), human clinical trials (3-5+ years), and FDA review. Don’t expect this treatment option in the near future.
Can I use this sustained-release semaglutide gel right now if I’m experiencing a weight loss plateau?
No, this treatment is not yet available for human use. It’s only been tested in laboratory animals. Continue your current semaglutide treatment as prescribed by your doctor and discuss weight loss plateau concerns with your healthcare provider for current options.
What health improvements did the sustained-release semaglutide show beyond weight loss?
In obese rats, the sustained-release formulation significantly reduced total cholesterol, improved liver enzyme markers (ALT and AST), and enhanced glucose tolerance without causing dangerously low blood sugar, suggesting broader metabolic benefits beyond weight loss alone.
Why do people experience weight loss plateaus with semaglutide, and how does this gel help?
Weight loss plateaus occur when the body adapts to medication peaks and valleys from regular injections. The sustained-release gel maintains steady medication levels continuously, preventing this adaptation and allowing weight loss to continue past the typical plateau point.
Want to Apply This Research?
- Users currently on semaglutide could track weight loss patterns weekly and note when plateaus occur (no weight change for 2+ weeks). This data helps identify individual plateau timing and severity, which would be valuable for comparing to future sustained-release options.
- While this specific treatment isn’t available yet, users can prepare by tracking their current weight loss response to semaglutide, documenting plateau experiences, and discussing sustained-release options with their healthcare provider when they become available. Users could also monitor metabolic markers (cholesterol, liver enzymes) that this research suggests improve with sustained-release delivery.
- Establish a baseline of current weight loss patterns, plateau timing, and metabolic health markers. When sustained-release semaglutide becomes available, compare new results to this baseline to assess whether the new delivery method provides the predicted benefits of continuous weight loss and improved metabolic markers.
This research describes early-stage laboratory testing in animals and does not represent approved human treatment. Semaglutide is a prescription medication that should only be used under medical supervision. Do not attempt to modify, create, or self-administer semaglutide formulations. If you’re currently taking semaglutide and experiencing weight loss plateaus, discuss your concerns with your healthcare provider about evidence-based options. This article is for educational purposes and should not replace professional medical advice. Future availability and safety of sustained-release semaglutide formulations in humans has not been established.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.